Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Henry

Showing results (691-700 of 733) with videos related to

Pageof 74
Sort By:
Antimicrobial Agents and Chemotherapy|January 30, 2008
Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replicationPeiyong Huang, Dane A Goff, Qi Huang, et al.
The Journal of Clinical Investigation|June 14, 2022
Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitisSojin Lee, Taofeek O Usman, Jun Yamauchi, et al.
Neurourology and Urodynamics|April 24, 2025
Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping Study: Methods and Baseline Urinary Symptoms by Age and SexGiulia M Ippolito, Kimberly Kenton, Catherine S Bradley, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Blood|December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
The Journal of Urology|November 8, 2017
Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort StudyAnne P Cameron, Christina Lewicky-Gaupp, Abigail R Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 20, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLCPere Gascón, Rajnish Nagarkar, Martin Šmakal, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2018
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary AngioedemaWilliam R Lumry, Timothy Craig, Bruce Zuraw, et al.
Pageof 74

Showing results (691-700 of 733) with videos related to

Sort By:
Pageof 74
Antimicrobial Agents and Chemotherapy|January 30, 2008
Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replicationPeiyong Huang, Dane A Goff, Qi Huang, et al.
The Journal of Clinical Investigation|June 14, 2022
Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitisSojin Lee, Taofeek O Usman, Jun Yamauchi, et al.
Neurourology and Urodynamics|April 24, 2025
Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping Study: Methods and Baseline Urinary Symptoms by Age and SexGiulia M Ippolito, Kimberly Kenton, Catherine S Bradley, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Blood|December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
The Journal of Urology|November 8, 2017
Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort StudyAnne P Cameron, Christina Lewicky-Gaupp, Abigail R Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 20, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLCPere Gascón, Rajnish Nagarkar, Martin Šmakal, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2018
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary AngioedemaWilliam R Lumry, Timothy Craig, Bruce Zuraw, et al.
Pageof 74